BioCentury | Feb 24, 2003
Company News

Incyte Genomics Inc., Maxia deal

...INCY completed its previously announced acquisition of Maxia, a developer of small molecule protein phosphatase inhibitors...
...in clinical milestones (see BioCentury, Nov. 18, 2002). Incyte Genomics Inc. (INCY), Palo Alto, Calif. Maxia Pharmaceuticals Inc....
BioCentury | Nov 18, 2002
Company News

Incyte Genomics Inc., Maxia deal

...INCY announced that it will acquire Maxia, a developer of small molecule protein phosphatase inhibitors, for...
...said Maxia's programs in cancer and inflammation complement its small molecule and protein therapeutic programs. Maxia's...
...II testing for cervical dysplasia, a precancerous condition. Incyte Genomics Inc. (INCY), Palo Alto, Calif. Maxia Pharmaceuticals Inc....
BioCentury | Nov 18, 2002
Strategy

Integration II

...was reflected in moves last week by two of these companies. Incyte Genomics Inc. purchased Maxia Pharmaceuticals Inc....
...of Maxia (San Diego, Calif.). Maxia develops small molecule protein phosphatase inhibitors, and INCY said Maxia's...
...the next year, INCY said it plans to hire 80-100 scientists, including those from the Maxia...
BioCentury | Nov 18, 2002
Finance

M&A crystal ball

...in stock for its stem cell technologies. Incyte Genomics Inc. (INCY, Palo Alto, Calif.) acquired Maxia Pharmaceuticals Inc....
BioCentury | Nov 18, 2002
Strategy

Headcount shifts

...add 80-100 next year to support drug discovery; current headcount does not account for planned Maxia...
BioCentury | Nov 12, 2002
Top Story

Incyte cuts staff, buys Maxia

...next year to support its drug discovery programs. Separately, INCY announced that it will acquire Maxia...
...said Maxia's programs in cancer and inflammation complement its small molecule and protein therapeutic programs. Maxia's...
BioCentury | Jun 10, 2002
Company News

TargeGen management update

...Business: Cancer, Cardiovascular Hired: Wood Erwin as VP of finance and CFO, formerly CFO at Maxia Pharmaceuticals Inc. WIR...
BioCentury | Apr 8, 2002
Company News

VitaGen management update

...therapy, Transplant Hired: Richard Piazza as CEO and a director, formerly president and CEO at Maxia Pharmaceuticals Inc. WIR...
BioCentury | Apr 3, 2002
Company News

Piazza returns to VitaGen as CEO

...in 1999 to join nutraceutical play PharmaPrint as president and CEO, and in 2001 joined Maxia...
BioCentury | Jan 14, 2002
Finance

Hat in Hand?

...$12.2M BioNumerik $12.0M Withdrew IPO on 11/01 Xanthon $12.0M Pharmadigm $12.0M Metabolex $10.8M GeneMachines $10.7M Maxia...
Items per page:
1 - 10 of 29
BioCentury | Feb 24, 2003
Company News

Incyte Genomics Inc., Maxia deal

...INCY completed its previously announced acquisition of Maxia, a developer of small molecule protein phosphatase inhibitors...
...in clinical milestones (see BioCentury, Nov. 18, 2002). Incyte Genomics Inc. (INCY), Palo Alto, Calif. Maxia Pharmaceuticals Inc....
BioCentury | Nov 18, 2002
Company News

Incyte Genomics Inc., Maxia deal

...INCY announced that it will acquire Maxia, a developer of small molecule protein phosphatase inhibitors, for...
...said Maxia's programs in cancer and inflammation complement its small molecule and protein therapeutic programs. Maxia's...
...II testing for cervical dysplasia, a precancerous condition. Incyte Genomics Inc. (INCY), Palo Alto, Calif. Maxia Pharmaceuticals Inc....
BioCentury | Nov 18, 2002
Strategy

Integration II

...was reflected in moves last week by two of these companies. Incyte Genomics Inc. purchased Maxia Pharmaceuticals Inc....
...of Maxia (San Diego, Calif.). Maxia develops small molecule protein phosphatase inhibitors, and INCY said Maxia's...
...the next year, INCY said it plans to hire 80-100 scientists, including those from the Maxia...
BioCentury | Nov 18, 2002
Finance

M&A crystal ball

...in stock for its stem cell technologies. Incyte Genomics Inc. (INCY, Palo Alto, Calif.) acquired Maxia Pharmaceuticals Inc....
BioCentury | Nov 18, 2002
Strategy

Headcount shifts

...add 80-100 next year to support drug discovery; current headcount does not account for planned Maxia...
BioCentury | Nov 12, 2002
Top Story

Incyte cuts staff, buys Maxia

...next year to support its drug discovery programs. Separately, INCY announced that it will acquire Maxia...
...said Maxia's programs in cancer and inflammation complement its small molecule and protein therapeutic programs. Maxia's...
BioCentury | Jun 10, 2002
Company News

TargeGen management update

...Business: Cancer, Cardiovascular Hired: Wood Erwin as VP of finance and CFO, formerly CFO at Maxia Pharmaceuticals Inc. WIR...
BioCentury | Apr 8, 2002
Company News

VitaGen management update

...therapy, Transplant Hired: Richard Piazza as CEO and a director, formerly president and CEO at Maxia Pharmaceuticals Inc. WIR...
BioCentury | Apr 3, 2002
Company News

Piazza returns to VitaGen as CEO

...in 1999 to join nutraceutical play PharmaPrint as president and CEO, and in 2001 joined Maxia...
BioCentury | Jan 14, 2002
Finance

Hat in Hand?

...$12.2M BioNumerik $12.0M Withdrew IPO on 11/01 Xanthon $12.0M Pharmadigm $12.0M Metabolex $10.8M GeneMachines $10.7M Maxia...
Items per page:
1 - 10 of 29